Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Vildagliptin

 

A new DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

 

Vildagliptin is a highly selective, reversible and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4). In this review, the authors discuss the characteristics and clinical experience with vildagliptin.

 

Introduction

Asia is in the midst of an epidemic of type 2 diabetes. The key to reducing the burden of diabetes and its complications lies in attaining optimal glycaemic control as well as reduction of other cardiovascular risk factors, including blood pressure, hypercholes-terolaemia and microalbuminuria. Whilst there are a variety of glucoselowering agents available for the treatment of type 2 diabetes with differing mechanisms of action, side effects, including weight gain and the risk of hypoglycaemia, have been the main obstacles against achievement of glycaemic targets, especially among overweight patients. This treatment. gap is highlighted by the recent controversy surrounding the outcome of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, in which subjects who received intensive glucose control had increased weight gain, increased risk of hypoglycaemia and an increased risk of death during the study. New treatments based on the incretin pathway have recently emerged, and encouraging data have accumulated to suggest that agents in this class may provide a much-needed treatment alternative, as well as address an important clinical need.

 

The Incretin Pathway as a Therapeutic Target in Type 2 Diabetes

'The incretin effect refers to the observation that insulin secretion is augmented following orally administered glucose compared to identical plasma glucose levels achieved by intravenous glucose infusion. 'This is now known to be mediated by two gut peptides, glucagon-like peptide-1 (GLP-1), produced by the L cells of the ileum, and the glucose-dependent insulinotropic polypeptide (GIP), produced by the K cells in the duodenum and jejunum. Among these, GLP-1 has been explored as a therapeutic strategy in the treatment of type 2 diabetes, as the insulinotropic effects of GLP-1 persist in patients with type 2 diabetes, compared to GIP, which has minimal glucose-lowering effects in subjects with type 2 diabetes.

In addition to enhancing glucosedependent insulin secretion, GLP-1 also suppresses glucagon secretion in a glucose-dependent manner. This has additional beneficial effects, including lowering fasting glucose, improving postprandial glycaemic control and improving hepatic insulin resistance. Other beneficial properties include delayed gastric emptying arid gut motility, which further reduces postprandial glucose excursion, and reducing appetite, food intake and weight. (Figure 1)

vildagliptin

The main obstacle against the use of GLP-1 as a potential treatment for type 2 diabetes is its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves off the N-terminal dipeptides (His-Ala) from GLP-1 (7-36), thereby inactivating it, resulting in its short half-life of only 2 minutes.

There are currently several agents developed to target the incretin pathway as therapeutic agents in type 2 diabetes. These include the GLP-1 mimetics, such as exenatide and liraglutide, and orally administered inhibitors of DPP-4, such as sitagliptin, vildagliptin and saxagliptin. in general, the metabolic benefits, including lowering of blood glucose and weight loss, are greater with GLP-1 mimetics compared with the DPP-4 inhibitors, presumably due to the higher levels of GLP-1 achieved. However, certain gastrointestinal side effects of GLP-1 mimetics such as nausea and vomiting are usually not seen in patients treated with DPP-4 inhibitors, likewise due to the lower GLP-1 levels achieved. Whilst sitagliptin is the first DPP-4 inhibitor available in most countries, vildagliptin is now available in many countries in Europe. This current article will review the characteristics and clinical experience with this DPP-4 inhibitor.

1    2    3    4    5

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer